Rankings
▼
Calendar
BCRX Q1 2019 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
BCRX
BioCryst Pharmaceuticals, Inc.
$2B
Q1 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$6M
+48.1% YoY
Gross Profit
$4M
74.8% margin
Operating Income
-$29M
-498.2% margin
Net Income
-$31M
-527.5% margin
EPS (Diluted)
$-0.28
QoQ Revenue Growth
+115.7%
Cash Flow
Operating Cash Flow
-$27M
Free Cash Flow
-$27M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$142M
Total Liabilities
$120M
Stockholders' Equity
$23M
Cash & Equivalents
$35M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$6M
$4M
+48.1%
Gross Profit
$4M
$4M
+14.7%
Operating Income
-$29M
-$22M
-32.0%
Net Income
-$31M
-$26M
-20.5%
Revenue Segments
Royalty
$2M
39%
Collaborative and Other Research and Development
$2M
32%
Product
$2M
29%
← FY 2019
All Quarters
Q2 2019 →